Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - Findings from an in vivo SPECT study

Schizophrenia Research

Volumn 88, Issue 1-3, 2006, Pages 179-186

  Voruganti, Lakshmi N P ^a   Awad, A George ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic medications; Dopamine; Dysphoria; Schizophrenia; Subjective effects

Indexed keywords

DOPAMINE; METIROSINE;

ADULT; AKATHISIA; AKINESIA; ALERTNESS; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISTRESS SYNDROME; DYSPHORIA; FEMALE; HUMAN; MALE; MENTAL DISEASE; MENTAL HEALTH; MOTIVATION; PHENOMENOLOGY; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOSOCIAL WITHDRAWAL; RATING SCALE; RIGIDITY; SCHIZOPHRENIA; STRIATE CORTEX; SUBSTANCE ABUSE;

ADULT; ALPHA-METHYLTYROSINE; CATECHOLAMINES; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; ENZYME INHIBITORS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOOD DISORDERS; SCHIZOPHRENIA; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33750626892     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.07.012     Document Type: Article

References (34)

1. Awad A.G. Subjective response to neuroleptic in schizophrenia. Schizophr. Bull. 19 (1993) 609-618
2. Awad A.G., and Hogan T.P. Early treatment events and prediction of response to neuroleptic in schizophrenia. Prog. Neuro-psychopharmacol Biol. Psychiatry 9 (1985) 585-588
3. Awad A.G., and Voruganti L. Impact of novel antipsychotic drugs. CNS Drugs 18 13 (2004) 877-893
4. Awad A.G., and Voruganti L.N.P. Neuroleptic dysphoria, comorbid drug abuse in schizophrenia and the emerging science of subjective tolerability. J. Dual Diagn. 1 (2005) 83-93
5. Awad A.G., Voruganti L.N.P., and Heslegrave R.J. The aim of antipsychotic medication: where are they and are they being achieved. CNS Drugs 4 (1995) 8-16
6. Awad A.G., Hogan T.P., Voruganti L.N.P., and Heslegrave R.J. Patient's subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 10 Supple. 3 (1995) 123-132
7. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
8. Bellmaker R.H., and Wald D. Haloperidol in normals. Br. J. Psychiatry 131 (1977) 222-223
9. Bressan R.H., and Crippa J.A. The role of dopamine in reward and pleasure behaviour - review of data from pre-clinical studies. Acta Psychiatr. Scand. III Suppl. 427 (2005) 14-21
10. Chambers R.A., Krystal J.H., and Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 50 (2001) 71-83
11. De Haan L., van Bruggen M., Lavalaye J., Booij J., Dugmans P., and Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am. J. Psychiatry 160 2 (2003) 303-309
12. De Haan L., Booij J., Lavalye J., van Amerlsvoort T., and Linszen D. Subjective experiences during dopamine depletion. Am. J. Psychiatry 162 (2005) 1755
13. Endicott J. History, evolution and diagnosis of premenstrual dysphoric disorder. J. Clin. Psychiatry 61 (2000) 5-8
14. Fibiger H.C., and Philips A.G. Reward, Motivation, Cognition: Psychobiology of Mesotelencephalic Dopamine System. In: Mouncastle V.B., Bloom F.E., and Geyer S.R. (Eds). Handbook of Physiology: The Nervous System IV (1986), American Psychological Society, Bethesda 647-675
15. Fujeta M., Ferhoeff P.L.G., Varrone A., Zoghbi S.S., Baldwin R.M., Jatlow P.A., Anderson G.M., Seibyl J.B., and Innis R.B. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy human. Eur. J. Pharmacol. 387 (2000) 179-188
16. Haertzen C.A. Addiction Research Centre Inventory (ARCI): development of a general drug estimation scale. J. Nerv. Ment. Dis. 141 (1965) 300-307
17. Hogan T.P., Awad A.G., and Eastwood M.R. A self-report scale predictive of drug complaince in schzophrenics: reliability and discrimnate ability. Psychol. Med. 13 (1983) 177-183
18. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 7 (2003) 1081-1090
19. Kay S., Fiszbein A., and Opler L. The Positive and Negative Syndromes Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261
20. Laruelle M., D'Souza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., Seibyl J.P., Zoghbi S.S., Bowers M.B., Jatlow P., Charney D.S., and Innis R.B. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17 (1997) 162-174
21. Marder S.R. Limitations of dopamine in D2 and the search for novel antipsychotic strategies. Neuropsychopharmacology 21 S6 (1999) S117-S121
22. McNair D.M., Lorr M., and Droppleman L. Manual for the Profile of Mood States (1992), Educational and Industrial Testing Services, San Diego, CA
23. Russell P., Hagenmeyer-Houser S.H., and Sanberg P.R. Haloperidol-induced emotional defecation: possible model for neuroleptic anxiety syndrome. Psychopharmacology 91 (1987) 45-49
24. Simpson G., and Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212 (1970) 11-19
25. Singh M.M., and Smith J.M. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis. Ner. Syst. 37 (1976) 191-196
26. Van Putten T., and May P.R.A. Subjective response as a predictor of outcome in pharmacotherapy. Arch. Gen. Psychiatry 35 (1978) 477-480
27. Van Putten T., May P.R.A., Marder R., and Wittmann L.A. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry 38 (1981) 187-190
28. Verhoff N.P., Christensen B.R., Hussy D., Lee M., Papatheodorou G., and Rapur S. Effects of catecholamine depletion on D2 receptor binding, motivation and attentiveness in humans: a replication study. Pharmacol. Biochem. Behav. 74 (2003) 425-432
29. Voruganti L.N.P., and Awad A.G. Neuroleptic dysphoria - towards new synthesis. Psychopharmacology 171 (2004) 121-132
30. Voruganti L.N.P., and Awad A.G. Is neuroleptic dysphoria a variant of extrapyramidal side effects?. Can. J. Psychiatry 49 (2004) 285-289
31. Voruganti L.N.P., and Awad A.G. Brain imaging research on subjective response to psychotropic drugs. Acta Psychiatr. Scand. Suppl 427 (2005) 22-28
32. Voruganti L.N.P., Heslegrave R.J., and Awad A.G. Neuroleptic dysphria may be the missing link between schizophrenia and substance abuse. J. Nerv. Ment. Dis. 185 (1997) 463-465
33. Voruganti L., Cortese L., Ouyewumi L., Cernovsky Z., Zirul S., and Awad A.G. Comparative evaluation of conventional and new antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr. Res. 43 (2000) 135-145
34. Voruganti L.N.P., Slomaka P., Zabel P., Costa G., So A., Mattar A., and Awad A.G. Subjective effects of AMPT induced dopamine depletion in schizophrenia: correlation between dysphoria response and striatal D2 binding ratios and SOPECTS imaging. Neuropsychopharmacology 25 (2001) 642-650